These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37507070)

  • 41. Impact of Anti-IL5 Therapies on Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study.
    Rojo-Tolosa S; González-Gutiérrez MV; Jiménez-Gálvez G; Sánchez-Martínez JA; Pineda-Lancheros LE; Gálvez-Navas JM; Jiménez-Morales A; Pérez-Ramírez C; Morales-García C
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768331
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Structured Approach to Specialist-referred Difficult Asthma Patients Improves Control of Comorbidities and Enhances Asthma Outcomes.
    Tay TR; Lee J; Radhakrishna N; Hore-Lacy F; Stirling R; Hoy R; Dabscheck E; O'Hehir R; Hew M
    J Allergy Clin Immunol Pract; 2017; 5(4):956-964.e3. PubMed ID: 28284780
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up.
    Desrosiers M; Diamant Z; Castelnuovo P; Hellings PW; Han JK; Peters AT; Silver J; Smith SG; Fuller A; Sousa AR; Chan RH; Gevaert P;
    Int Forum Allergy Rhinol; 2024 Jan; 14(1):18-31. PubMed ID: 37345861
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms.
    Littner MR; Leung FW; Ballard ED; Huang B; Samra NK;
    Chest; 2005 Sep; 128(3):1128-35. PubMed ID: 16162697
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis.
    Numata T; Nakayama K; Utsumi H; Kobayashi K; Yanagisawa H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
    BMC Pulm Med; 2019 Oct; 19(1):176. PubMed ID: 31606052
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
    Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
    Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
    Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: A real-world database study in Japan.
    Nagase H; Tamaoki J; Suzuki T; Nezu Y; Akiyama S; Cole AL; Yang S; Mu G; Katsumata M; Komatsubara M; Alfonso-Cristancho R
    Pulm Pharmacol Ther; 2022 Aug; 75():102130. PubMed ID: 35714883
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prospective Open-Label Study of 48-Week Subcutaneous Administration of Mepolizumab in Japanese Patients With Severe Eosinophilic Asthma.
    Kurosawa M; Sutoh E
    J Investig Allergol Clin Immunol; 2019; 29(1):40-45. PubMed ID: 29957591
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-world outcomes of mepolizumab treatment in severe eosinophilic asthma patients - retrospective cohort study in Slovakia.
    Jesenak M; Vanecek V; Ondrusova M; Urdova V; Dostalova K; Hochmuth L
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2023 Sep; 167(3):272-280. PubMed ID: 37439266
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of comorbidities in COPD clinical control criteria. The CLAVE study.
    Almagro P; Soler-Cataluña JJ; Huerta A; González-Segura D; Cosío BG;
    BMC Pulm Med; 2024 Jan; 24(1):6. PubMed ID: 38166965
    [TBL] [Abstract][Full Text] [Related]  

  • 52. From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.
    Pavord ID; Bel EH; Bourdin A; Chan R; Han JK; Keene ON; Liu MC; Martin N; Papi A; Roufosse F; Steinfeld J; Wechsler ME; Yancey SW
    Allergy; 2022 Mar; 77(3):778-797. PubMed ID: 34402066
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma.
    Gunsoy NB; Cockle SM; Yancey SW; Keene ON; Bradford ES; Albers FC; Pavord ID
    J Allergy Clin Immunol Pract; 2018; 6(3):874-882.e4. PubMed ID: 29258789
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness of mepolizumab therapy in patients with severe eosinophilic asthma: Austrian real-life data.
    Renner A; Marth K; Patocka K; Idzko M; Pohl W
    Pulm Pharmacol Ther; 2020 Oct; 64():101946. PubMed ID: 32949705
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Results in clinical practice in the treatment of severe eosinophilic asthma with mepolizumab: a real-life study.
    Enríquez-Rodríguez AI; Hermida Valverde T; Romero Álvarez P; López-González FJ; Gullón Blanco JA; Expósito Villegas AR; Escobar Fernández MJ; Beristáin Urquiza AM; Alonso Fernández MÁ; Gutiérrez Rodríguez M; Castaño De Las Pozas G; Jiménez Pérez J; Fernández Mellado R; García Clemente MM; Casan Clara P
    J Asthma; 2022 May; 59(5):1005-1011. PubMed ID: 33653213
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comorbidities associated with adult asthma: a population-based matched cohort study in Finland.
    Lemmetyinen RE; Toppila-Salmi SK; But A; Renkonen R; Pekkanen J; Haukka J; Karjalainen J
    BMJ Open Respir Res; 2024 Mar; 11(1):. PubMed ID: 38485249
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-IL5/IL5R Treatment in COPD: Should We Target Oral Corticosteroid-Dependent Patients?
    Laroche J; Pelletier G; Boulay MÈ; Côté A; Godbout K
    Int J Chron Obstruct Pulmon Dis; 2023; 18():755-763. PubMed ID: 37180748
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment trends in patients with asthma-COPD overlap syndrome in a COPD cohort: findings from a real-world survey.
    Ding B; Small M
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1753-1763. PubMed ID: 28670116
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of five clusters of comorbidities in a longitudinal Japanese chronic obstructive pulmonary disease cohort.
    Chubachi S; Sato M; Kameyama N; Tsutsumi A; Sasaki M; Tateno H; Nakamura H; Asano K; Betsuyaku T;
    Respir Med; 2016 Aug; 117():272-9. PubMed ID: 27492541
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gastroesophageal reflux symptoms and nasal symptoms affect the severity of bronchitis symptoms in patients with chronic obstructive pulmonary disease.
    Hasegawa K; Sato S; Tanimura K; Fuseya Y; Uemasu K; Hamakawa Y; Sato A; Mishima M; Muro S; Hirai T
    Respir Investig; 2018 May; 56(3):230-237. PubMed ID: 29773294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.